Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H5N1 Vaccine Dose Finding for IVIG Development
NCT00383071Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2006
- Primary completion
- Mar 2010
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of Influenza A (H5N1) virus vaccine in Avian Influenza (AI) (4 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety of H5N1 Vaccine as Measured by Adverse Events at 84 days. Started Aug 2006; status: terminated.
02
Drugs
Influenza A (H5N1) virus vaccine
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT00383071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383071.